---
CHAMBERLAIN UNIVERSITY NR565
EXAM \ NR565 ADVANCED
PHARMACOLOGY MIDTERM EXAM
2026/2027 AND STUDY
**Q1. What is the legal term for the authority to prescribe medications,
and who regulates it at the state level?**
**A1. Prescriptive authority.** It is regulated by the state's health
professional boards (e.g., Board of Nursing, Board of Medicine), not the
federal government .
**Q2. A patient asks why their prescription costs less for the generic
version. What is the key difference between a generic and brand-name
drug?**
**A2. Generics are equivalent in active ingredient, strength, and
bioavailability but are typically sold at a lower cost after the brand-
name patent expires** .
**Q3. A nurse practitioner is writing a prescription for a Schedule II
controlled substance. According to DEA regulations, what critical
information must be included on the prescription?**
,**A3.** The prescription must include the patient's name and address,
the practitioner's name, address, and **DEA number**, the drug name,
strength, dosage form, and quantity prescribed. It cannot be refilled; a
new prescription is required for each fill .
**Q4. What is the primary purpose of a state's Prescription Drug
Monitoring Program (PDMP)?**
**A4. To help identify patients who may be at risk for overdose or
substance misuse.** It allows providers to review a patient's controlled
substance prescription history .
**Q5. What is the difference between full, independent prescriptive
authority and limited prescriptive authority for an APRN?**
**A5. Full authority** means the APRN can prescribe independently
without physician oversight. **Limited authority** subjects the APRN
to restrictions such as supervision requirements or limitations on the
drug classes they can prescribe .
**Q6. A patient presents with a new prescription. You explain the drug
is an "agonist" at a specific receptor. What does this mean?**
**A6. An agonist binds to a receptor and activates it, producing a
response** .
**Q7. A patient is taking a drug that is a "noncompetitive antagonist."
How does this drug's mechanism of action differ from a competitive
antagonist?**
,**A7. A noncompetitive antagonist binds to a different site on the
receptor (allosteric site) and reduces the maximal response the agonist
can produce, regardless of the agonist concentration** .
**Q8. A drug is noted to have a "narrow therapeutic index." What
implication does this have for patient management?**
**A8. It requires precise dosing and therapeutic drug monitoring
because small changes in dose or metabolism can lead to toxicity or
therapeutic failure** .
**Q9. A patient reports severe toxicity from a standard dose of a
medication. A pharmacogenomic test reveals they are a "poor
metabolizer" for the CYP2D6 enzyme. How does this genetic variant
affect drug response?**
**A9. As a poor metabolizer, the patient has reduced ability to
metabolize drugs that are substrates for CYP2D6, leading to higher-
than-expected drug levels and an increased risk for toxicity at standard
doses** .
**Q10. What is the primary function of the FDA's "Black Box Warning"
on a medication?**
**A10. It is the highest-level safety warning to alert prescribers to
serious or life-threatening risks, such as fetal harm or suicidal ideation,
and to provide ways to reduce or prevent harm** .
### Pharmacokinetics and Pharmacodynamics Across the Lifespan
, **Q11. A patient with chronic kidney disease is prescribed a drug
primarily eliminated by the kidneys. What pharmacokinetic change is
most likely, and what intervention is needed?**
**A11. Drug accumulation is likely due to impaired clearance. The
intervention is to adjust the dose or dosing interval based on the
patient's renal function** .
**Q12. A pregnant patient is concerned about medication safety.
Which drug characteristic most readily allows a drug to cross the
placenta?**
**A12. Lipid-soluble, non-ionized, small molecular weight drugs cross
the placenta most readily** .
**Q13. Why are pediatric patients under 1 year of age more
susceptible to adverse drug effects than older children?**
**A13. Their organ systems for absorption, distribution, metabolism,
and excretion are immature. For example, hepatic metabolism and
renal filtration are not yet fully developed, requiring weight-based and
age-specific dosing** .
**Q14. An older adult patient reports feeling very dizzy and
lightheaded after starting a low-dose beta-blocker. What age-related
pharmacodynamic change is most likely contributing to this?**
**A14. Older adults often show increased sensitivity to beta-blockers
due to age-related changes in receptor sensitivity and homeostatic
CHAMBERLAIN UNIVERSITY NR565
EXAM \ NR565 ADVANCED
PHARMACOLOGY MIDTERM EXAM
2026/2027 AND STUDY
**Q1. What is the legal term for the authority to prescribe medications,
and who regulates it at the state level?**
**A1. Prescriptive authority.** It is regulated by the state's health
professional boards (e.g., Board of Nursing, Board of Medicine), not the
federal government .
**Q2. A patient asks why their prescription costs less for the generic
version. What is the key difference between a generic and brand-name
drug?**
**A2. Generics are equivalent in active ingredient, strength, and
bioavailability but are typically sold at a lower cost after the brand-
name patent expires** .
**Q3. A nurse practitioner is writing a prescription for a Schedule II
controlled substance. According to DEA regulations, what critical
information must be included on the prescription?**
,**A3.** The prescription must include the patient's name and address,
the practitioner's name, address, and **DEA number**, the drug name,
strength, dosage form, and quantity prescribed. It cannot be refilled; a
new prescription is required for each fill .
**Q4. What is the primary purpose of a state's Prescription Drug
Monitoring Program (PDMP)?**
**A4. To help identify patients who may be at risk for overdose or
substance misuse.** It allows providers to review a patient's controlled
substance prescription history .
**Q5. What is the difference between full, independent prescriptive
authority and limited prescriptive authority for an APRN?**
**A5. Full authority** means the APRN can prescribe independently
without physician oversight. **Limited authority** subjects the APRN
to restrictions such as supervision requirements or limitations on the
drug classes they can prescribe .
**Q6. A patient presents with a new prescription. You explain the drug
is an "agonist" at a specific receptor. What does this mean?**
**A6. An agonist binds to a receptor and activates it, producing a
response** .
**Q7. A patient is taking a drug that is a "noncompetitive antagonist."
How does this drug's mechanism of action differ from a competitive
antagonist?**
,**A7. A noncompetitive antagonist binds to a different site on the
receptor (allosteric site) and reduces the maximal response the agonist
can produce, regardless of the agonist concentration** .
**Q8. A drug is noted to have a "narrow therapeutic index." What
implication does this have for patient management?**
**A8. It requires precise dosing and therapeutic drug monitoring
because small changes in dose or metabolism can lead to toxicity or
therapeutic failure** .
**Q9. A patient reports severe toxicity from a standard dose of a
medication. A pharmacogenomic test reveals they are a "poor
metabolizer" for the CYP2D6 enzyme. How does this genetic variant
affect drug response?**
**A9. As a poor metabolizer, the patient has reduced ability to
metabolize drugs that are substrates for CYP2D6, leading to higher-
than-expected drug levels and an increased risk for toxicity at standard
doses** .
**Q10. What is the primary function of the FDA's "Black Box Warning"
on a medication?**
**A10. It is the highest-level safety warning to alert prescribers to
serious or life-threatening risks, such as fetal harm or suicidal ideation,
and to provide ways to reduce or prevent harm** .
### Pharmacokinetics and Pharmacodynamics Across the Lifespan
, **Q11. A patient with chronic kidney disease is prescribed a drug
primarily eliminated by the kidneys. What pharmacokinetic change is
most likely, and what intervention is needed?**
**A11. Drug accumulation is likely due to impaired clearance. The
intervention is to adjust the dose or dosing interval based on the
patient's renal function** .
**Q12. A pregnant patient is concerned about medication safety.
Which drug characteristic most readily allows a drug to cross the
placenta?**
**A12. Lipid-soluble, non-ionized, small molecular weight drugs cross
the placenta most readily** .
**Q13. Why are pediatric patients under 1 year of age more
susceptible to adverse drug effects than older children?**
**A13. Their organ systems for absorption, distribution, metabolism,
and excretion are immature. For example, hepatic metabolism and
renal filtration are not yet fully developed, requiring weight-based and
age-specific dosing** .
**Q14. An older adult patient reports feeling very dizzy and
lightheaded after starting a low-dose beta-blocker. What age-related
pharmacodynamic change is most likely contributing to this?**
**A14. Older adults often show increased sensitivity to beta-blockers
due to age-related changes in receptor sensitivity and homeostatic
